Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Core Viewpoint - Organon's NEXPLANON has received U.S. FDA sNDA approval for an extended duration of use up to five years, which includes data for use in women with varying BMIs [1] Group 1 - The approval allows NEXPLANON to be used for an extended period, enhancing its market potential [1] - The data supporting the approval includes information on its effectiveness and safety for women with different body mass indexes (BMIs) [1]